Clinical analysis of gefitinib in treatment of 30 elderly patients with advanced non-small-cell lung cancer

VernacularTitle:吉非替尼治疗老年人晚期非小细胞肺癌30例临床分析
Author: Yingmeng WU
Publication Type:Journal Article
Keywords: Lung tumor,non-small cell; Gefitinib; Targeting therapy; Aged
From: Chinese Journal of Primary Medicine and Pharmacy 2011;18(12):1625-1626
CountryChina
Language:Chinese
Abstract: Objective To investigate the efficacy and adverse reactions of gefitinib in treatment of elderly patients with advanced non-small-cell lung cancer.Methods 30 elderly patients with advanced non-small cell lung cancer were treatment with oral gefitinib,250mg/d,every 4 weeks for a treatment period.The efficacy,adverse reactions,quality of life were observed.Results Of 30 cases,the rate of complete response(CR) ,partial response(PR), stability of disease(SD) .progression of disease(PD) and disease control was 0.0% ,26.6% ,26.6% ,49.6% ,53.3% ,respectively;The disease control rate( 84.0% ) in adenocarcinoma was significantly higher than that in squamous cell carcinoma( 20.0% ) (x2 = 9.125, P < 0.01) ; The disease control rate (100.0% ) in stage- Ⅲ was significantly higher than that in stage Ⅳ(77.8%)(x2 =3.879,P<0.05);The median progression-free survival was 3.8 months, and median survival was 5.2 months;The most common toxicity was skin toxicity, hematologic toxicity was not observed.Conclusion As the first-line treatment for advanced NSCLC, gefitinib was effective and tolerable for the elderly.